Showing results 1 to 20 of 118
next >
| Preview | Issue Date | Title | Author(s) |
| 2014 | A demonstration of multiplex biosensing using whispering gallery mode microspheres positioned onto a microstructured optical fiber tip | Reynolds, T.; François, A.; Nicholls, S.; Monro, T.; Cote, G.L.; Optical Diagnostics and Sensing (14th : 2014 : San Francisco, CA., U.S.A.) |
| 2013 | A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial) | Maki, K.; Orloff, D.; Nicholls, S.; Dunbar, R.; Roth, E.; Curcio, D.; Johnson, J.; Kling, D.; Davidson, M. |
| 2016 | A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients | Banach, M.; Dinca, M.; Ursoniu, S.; Serban, M.; Howard, G.; Mikhailidis, D.; Nicholls, S.; Lip, G.; Glasser, S.; Martin, S.; Muntner, P.; Rysz, J.; Toth, P.; Sahebkar, A. |
| 2016 | A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia | Karlson, B.; Palmer, M.; Nicholls, S.; Lundman, P.; Barter, P. |
| 2013 | Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥50% reduction in high-risk patients: results from VOYAGER | Karlson, B.; Nicholls, S.; Lundman, P.; Palmer, M.; Barter, P. |
| 2014 | Achievement of combined goals of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol with three different statins: results from VOYAGER | Karlson, B.; Toth, P.; Palmer, M.; Barter, P.; Nicholls, S. |
| 2013 | Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: An analysis from the VOYAGER database | Palmer, M.; Nicholls, S.; Lundman, P.; Barter, P.; Karlson, B. |
| 2015 | Acute high-density lipoprotein therapies | Duong, M.; Di Bartolo, B.; Nicholls, S. |
| 2018 | ADCY9 genetic variants and cardiovascular outcomes with evacetrapib in patients with high-risk vascular disease: a nested case-control study | Nissen, S.; Pillai, S.; Nicholls, S.; Wolski, K.; Riesmeyer, J.; Weerakkody, G.; Foster, W.; McErlean, E.; Li, L.; Bhatnagar, P.; Ruotolo, G.; Lincoff, A. |
| 2018 | Advances in lipid-lowering therapy through gene-silencing technologies | Nordestgaard, B.; Nicholls, S.; Langsted, A.; Ray, K.; Tybjærg-Hansen, A. |
| 2017 | Aldosterone does not predict cardiovascular events following acute coronary syndrome in patients initially without heart failure | Pitts, R.; Gunzburger, E.; Ballantyne, C.; Barter, P.; Kallend, D.; Leiter, L.; Leitersdorf, E.; Nicholls, S.; Shah, P.; Tardif, J.; Olsson, A.; McMurray, J.; Kittelson, J.; Schwartz, G. |
| 2014 | Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from study of coronary atheroma by intravascular ultrasound: effect of rosuvastatin versus atorvastatin | Puri, R.; Nissen, S.; Shao, M.; Ballantyne, C.; Barter, P.; Chapman, M.; Erbel, R.; Libby, P.; Raichlen, J.; Uno, K.; Kataoka, Y.; Nicholls, S. |
| 2016 | Aortic atheroma burden predicts acute cerebrovascular events after transcatheter aortic valve implantation: insights from volumetric multislice computed tomography analysis | Kataoka, Y.; Puri, R.; Pisaniello, A.; Hammadah, M.; Qintar, M.; Uno, K.; Montarello, J.; Nicholls, S.; Worthley, S. |
| 2015 | Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: rationale and design of the ACCELERATE trial | Nicholls, S.; Lincoff, A.; Barter, P.; Brewer, H.; Fox, K.; Gibson, C.; Grainger, C.; Menon, V.; Montalescot, G.; Rader, D.; Tall, A.; McErlean, E.; Riesmeyer, J.; Vangerow, B.; Ruotolo, G.; Weerakkody, G.; Nissen, S. |
| 2018 | Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-outcomes randomized clinical trial | Schwartz, G.; Ballantyne, C.; Barter, P.; Kallend, D.; Leiter, L.; Leitersdorf, E.; McMurray, J.; Nicholls, S.; Olsson, A.; Shah, P.; Tardif, J.-C.; Kittelson, J. |
| 2015 | Atheroma progression in hyporesponders to statin therapy | Kataoka, Y.; St John, J.; Wolski, K.; Uno, K.; Puri, R.; Tuzcu, E.; Nissen, S.; Nicholls, S. |
| 2017 | Atrial fibrillation, progression of coronary atherosclerosis and myocardial infarction | Bayturan, O.; Puri, R.; Tuzcu, E.; Shao, M.; Wolski, K.; Schoenhagen, P.; Kapadia, S.; Nissen, S.; Sanders, P.; Nicholls, S. |
| 2016 | Biosensors for detecting stress in developing embryos | Purdey, M.; Saini, A.; McLennan, H.; Pullen, B.; Schartner, E.; Sutton-McDowall, M.; Thompson, J.; Monro, T.; Nicholls, S.; Abell, A.; Hutchinson, M.; Goldys, E.; SPIE BioPhotonics Australasia Conference (17 Oct 2016 - 19 Oct 2016 : Adelaide, Australia) |
| 2013 | C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy | Puri, R.; Nissen, S.; Libby, P.; Shao, M.; Ballantyne, C.; Barter, P.; Chapman, M.; Erbel, R.; Raichlen, J.; Uno, K.; Kataoka, Y.; Nicholls, S. |
| 2016 | CETP Inhibition in CVD prevention: an actual appraisal | Di Bartolo, B.; Takata, K.; Duong, M.; Nicholls, S. |
